Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Cholangiocarcinoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Mouth Neoplasms 1Metastatic NUT Carcinoma 1Laryngeal Neoplasms 1Klatskin Tumor 1Infiltrating Bladder Urothelial Carcinoma 1Hypopharyngeal Neoplasms 1HIV Infections 1Carcinoma 1Borderline Resectable Pancreatic Adenocarcinoma 1Bile Duct Neoplasms 1

Interventions

molibresib 1etoposide phosphate 1Platinum 1Etoposide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Metastatic NUT Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡